Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sensipar

Eli Lilly HQ

FDA clears Lilly’s lung cancer drug Portrazza

First biologic drug to be approved as first-line therapy for NSCLC

- PMLiVE

FDA approves Adapt Pharma’s opioid overdose nasal spray

Narcan aims to curb rise in deaths from opioid abuse

- PMLiVE

FDA clears Takeda’s oral multiple myeloma drug

Ninlaro is the first oral proteasome inhibitor to get a green light from the FDA

- PMLiVE

Amgen’s Kyprolis approved in Europe

Multiple myeloma drugwins licence three years after gaining US approval

- PMLiVE

Repatha’s price tag too rich for UK’s NICE

HTAbody turns the cholesterol-lowering antibody down in draft guidance

- PMLiVE

FDA deems Merck KGaA and Pfizer’s avelumab a breakthrough

Could become first-in-class treatment for Merkel cell carcinoma

Bristol-Myers Squibb (BMS) building

BMS closer to kidney cancer approval for Opdivo

Wins priority review for renal cell carcinoma

Teva Pharma logo

TEVA’s tardive dyskinesia drug wins FDA breakthrough status

SD-809 to be given development incentives

- PMLiVE

Amgen’s biosimilar shows clinical equivalence with Humira

ABP 501 as effective as AbbVie's blockbuster in phase III rheumatoid arthritis trial

- PMLiVE

At long last, Merck gets FDA panel backing for Bridion

Unanimous vote in favour of drug suggest it is back on course for approval

- PMLiVE

GSK bags FDA approval for severe asthma drug Nucala

Drug to be launched as soon as possible

Bristol-Myers Squibb (BMS) building

BMS’ Yervoy receives additional FDA approval

Gives the nod for Yervoy as adjuvant treatment option for melanoma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links